State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? When? | VuMedi

Moffitt Cancer Center

State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? When?

By Moffitt Cancer Center FEATURING Ariel Grajales-Cruz

By Moffitt Cancer Center FEATURING Ariel Grajales-Cruz

217 views

March 4, 2024

0 Comments

Login to view comments. Click here to Login